CLINICAL_TRIALS
ClinicalTrials.gov record update
Phase I Study Combining Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS) in Relapsed/Refractory EBV Positive Lymphoma Patients (PREVALE)
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT02973113
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:38:05.746036+00:00
- Published At
- 2021-07-21T00:00:00+00:00
- Record Updated At
- 2021-07-21
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["NonHodgkin Lymphoma", "Lymphoproliferative Disorders", "EBV Related Lymphoma", "EBV-Related PTLD", "Hodgkin Lymphoma", "EBV Related Non-Hodgkin\u0027s Lymphoma", "EBV Related Hodgkin\u0027s Lymphoma"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2021-07-21"- protocolSection.identificationModule.nctId
"NCT02973113"- protocolSection.identificationModule.officialTitle
"Phase I Study Combining Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS) in Relapsed/Refractory EBV Positive Lymphoma Patients (PREVALE)"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.